Skip to main content
Top
Published in: Pathology & Oncology Research 4/2011

01-12-2011 | Research

Watchful Waiting and Active Surveillance Approach in Patients with Low Risk Localized Prostatic Cancer: An Experience of Out-Patients Clinic with 12-Year Follow-Up

Authors: Sergey Kravchick, Ronit Peled, Shmuel Cytron

Published in: Pathology & Oncology Research | Issue 4/2011

Login to get access

Abstract

In this study we evaluated the safety of expectant approach in the patients with low risk prostate cancer in the reality of community based out-patients clinics. 48 men were enrolled into the study. The inclusion criteria were age ranged from 60 to 75 years and the Epstein criteria for low risk prostate cancer. Patients were managed expectantly while curative treatment was offered when indicated. Initial and final Charlson comorbidity index (CCI) and BMI were assessed for all men. Patients’ median follow-up was 81.1 ± 29.1 years. During this study 41.7% of the patients chose active forms of treatment. Cancer was found in 20.8% (n-10) of our patients. Two first sessions of re-biopsy diagnosed 92% of T1c upgrading. Six men with CCI ≥2 died from concomitant disease and no one died from PCa. Significant correlation was found between BMI and final CCI ≥2 (p-0.001). Expectant approach can be considered as self alternative to active treatment model in selected group of patients with well differentiated PCa, however 20.8% of these patients are still at risk of having aggressive form of cancer. Expectant approach is particular beneficial for the patients with CCI 1–2 and high BMI.
Literature
1.
go back to reference Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328PubMedCrossRef Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328PubMedCrossRef
2.
go back to reference Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374PubMedCrossRef Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374PubMedCrossRef
3.
go back to reference Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178(6):2359–2364, discussion 2364–5PubMedCrossRef Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI (2007) Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 178(6):2359–2364, discussion 2364–5PubMedCrossRef
4.
go back to reference Barocas DA, Cowan JE, Smith JA Jr, Carroll PR (2008) What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 180(4):1330–1334PubMedCrossRef Barocas DA, Cowan JE, Smith JA Jr, Carroll PR (2008) What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 180(4):1330–1334PubMedCrossRef
5.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
6.
go back to reference Nash PH, Bruce JE, Indudhara R, Shinohara K (1996) Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 155:607–609PubMedCrossRef Nash PH, Bruce JE, Indudhara R, Shinohara K (1996) Transrectal ultrasound guided prostatic nerve blockade eases systematic needle biopsy of the prostate. J Urol 155:607–609PubMedCrossRef
7.
go back to reference Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 54(6):1306–1313PubMedCrossRef Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI (2008) Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 54(6):1306–1313PubMedCrossRef
8.
go back to reference Bastian PJ, Mangold LA, Epstein JI, Partin AW (2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101(9):2001–2005PubMedCrossRef Bastian PJ, Mangold LA, Epstein JI, Partin AW (2004) Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101(9):2001–2005PubMedCrossRef
9.
go back to reference Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA (2010) The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 58(1):90–95, Epub 2009 Oct 23PubMedCrossRef Lee MC, Dong F, Stephenson AJ, Jones JS, Magi-Galluzzi C, Klein EA (2010) The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 58(1):90–95, Epub 2009 Oct 23PubMedCrossRef
10.
go back to reference Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172(5 Pt 2):S48–S50, discussion S50-1PubMedCrossRef Klotz L (2004) Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 172(5 Pt 2):S48–S50, discussion S50-1PubMedCrossRef
11.
go back to reference Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH (2006) Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50(3):475–482, Epub 2006 May 3PubMedCrossRef Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH (2006) Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50(3):475–482, Epub 2006 May 3PubMedCrossRef
12.
go back to reference Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S (2008) Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286–292PubMedCrossRef Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S (2008) Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113(2):286–292PubMedCrossRef
13.
go back to reference Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12):868–878PubMedCrossRef Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12):868–878PubMedCrossRef
14.
go back to reference Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH (2007) Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177(1):107–112, discussion 112PubMedCrossRef Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH (2007) Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177(1):107–112, discussion 112PubMedCrossRef
15.
go back to reference Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17):2095–2101PubMedCrossRef Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17):2095–2101PubMedCrossRef
16.
go back to reference Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8):1650–1659PubMedCrossRef Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8):1650–1659PubMedCrossRef
17.
go back to reference Stav K, Leibovici D, Sandbank J, Lindner A, Zisman A (2008) Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 71(3):399–403PubMedCrossRef Stav K, Leibovici D, Sandbank J, Lindner A, Zisman A (2008) Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 71(3):399–403PubMedCrossRef
18.
go back to reference Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C (2001) Marberger M Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 166(3):856–860PubMedCrossRef Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C (2001) Marberger M Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 166(3):856–860PubMedCrossRef
19.
go back to reference Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW (1999) Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 84(6):652–656PubMedCrossRef Post PN, Kil PJ, Hendrikx AJ, Janssen-Heijnen ML, Crommelin MA, Coebergh JW (1999) Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int 84(6):652–656PubMedCrossRef
Metadata
Title
Watchful Waiting and Active Surveillance Approach in Patients with Low Risk Localized Prostatic Cancer: An Experience of Out-Patients Clinic with 12-Year Follow-Up
Authors
Sergey Kravchick
Ronit Peled
Shmuel Cytron
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9400-0

Other articles of this Issue 4/2011

Pathology & Oncology Research 4/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine